Exhibit 99.4
Contact: Sandra Menta
610-738-6376
FOR IMMEDIATE RELEASE
- ---------------------
CEPHALON ANNOUNCES EXECUTIVE CHANGE
West Chester, PA June 11, 1999 Cephalon, Inc. (Nasdaq: CEPH) today
announced that Bruce A. Peacock, executive vice president and chief operating
officer will leave the company to become president and chief operating officer
of Orthovita Inc. in Malvern, PA.
"We appreciate Bruce's significant contributions during his tenure at
Cephalon," stated Frank Baldino, Jr., Ph.D., Cephalon's president and chief
executive officer. "He has an opportunity to be president of a good company, and
we wish him well."
Cephalon also announced that Robert P. Roche, Jr., will be appointed senior
vice president, sales and marketing. Over the past four and one half years,
Roche has managed the sales and marketing organization as vice president of that
department. Previously, Roche was director and vice president, worldwide
strategic product development, for SmithKline Beecham's (SB) $1.6 billion
central nervous system and gastrointestinal products business. He also was
managing director of SB's pharmaceutical operations in the Phillipines, and held
senior marketing positions in Canada and Spain and product planning
responsibility for SB in Latin America. Roche began his pharmaceutical career in
1982 as a U.S. pharmaceutical sales representative. Roche graduated from Colgate
University and received his MBA degree from The Wharton School, University of
Pennsylvania.
"Bob has been instrumental in building and managing a significant portion
of our commercial organization, and we look forward to his contributions in his
new capacity as senior vice president," said Dr. Baldino.
Cephalon, Inc., headquartered in West Chester, PA, is an international
biopharmaceutical company dedicated to the discovery, development and marketing
of products to treat neurological disorders, sleep disorders and cancer.
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking statements
provide our current expectations or forecasts of future events. These may
include statements regarding anticipated scientific progress on our research
programs, development of potential pharmaceutical products, prospects for
regulatory approval, manufacturing development and capabilities, market
prospects for our products, sales and earnings projections, and other statements
regarding matters that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements such as
"anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or
other words and terms of similar meaning. Our performance and financial results
could differ materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political conditions
affecting the biotechnology and pharmaceutical industries as well as more
specific risks and uncertainties such as those set forth below and in our
reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of these forward-
looking statements may prove to be incorrect. Therefore, you are cautioned not
to place too much reliance on any such factors or forward-looking statements.
Furthermore, we do not intend (and we are not obligated) to update publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise. This discussion is permitted by the Private Securities
Litigation Reform Act of 1995.
NOTE: Cephalon's press releases are posted on the Internet at the
company's Web site at http://www.cephalon.com. They are also available by fax
-----------------------
24 hours a day at no charge by calling PR Newswire's Company News On-Call at
800-758-5804, extension 134563.